The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4).
 
Eliza Anne Hawkes
Consulting or Advisory Role - AstraZeneca; BeiGene (Inst); Bristol Myers Squibb (Inst); Gilead Sciences (Inst); Janssen Oncology; Link healthcare (Inst); Merck Sharpe & Dohme (Inst); Novartis (Inst); Regeneron (Inst)
Speakers' Bureau - Abbvie (Inst); Regeneron; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gilead Sciences (Inst); Janssen-Cilag (Inst); Merck KGaA (Inst); Mundipharma (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Novartis; Regeneron; Samsung Bioepis; Takeda
Speakers' Bureau - AstraZeneca/MedImmune; IMBdx; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Dizal Pharma (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
 
Eva Maria Donato Martín
Consulting or Advisory Role - Incyte; Roche
Speakers' Bureau - Incyte; Roche
 
Amanda Núñez-García
No Relationships to Disclose
 
Geoffrey Chong
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene (Inst); Takeda (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dizal Pharma (Inst); Dizal Pharma (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Isofol Medical (Inst); Merck Serono (Inst); MorphoSys (Inst); Pharmacyclics (Inst); Regeneron (Inst); Seagen (Inst)
 
Manjusha Namuduri
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Ashish Risal
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Yuan Cheng
Employment - Regeneron
Stock and Other Ownership Interests - Novartis, Regeneron
 
Dina M Flink
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Min Zhu
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Siobhán Nolan
Employment - Regeneron Ireland
Stock and Other Ownership Interests - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Jurriaan Brouwer-Visser
No Relationships to Disclose
 
Aafia Chaudhry
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Srikanth R Ambati
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Hesham Mohamed
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Odronextamab related patents
 
Seok-Goo Cho
Stock and Other Ownership Interests - LucasBio, VigenCell